The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Chemoresistance and targeted therapies in ovarian and endometrial cancers
Open accessAbstract
// Kevin Brasseur 1 , Nicolas Gévry 2 and Eric Asselin 1 1 Research Group in Cellular Signaling, Department of Medical Biology, Canada Research Chair in Molecular Gyneco-Oncology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada 2 Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Boulevard de l’Université, Sherbrooke, QC, Canada Correspondence to: Eric Asselin, email: // Keywords : gynecological cancers, chemoresistance, targeted therapies, PI3K, estrogen Received : August 17, 2016 Accepted : November 30, 2016 Published : December 19, 2016 Abstract Gynecological cancers are known for being very aggressive at their advanced stages. Indeed, the survival rate of both ovarian and endometrial cancers is very low when diagnosed lately and the success rate of current chemotherapy regimens is not very efficient. One of the main reasons for this low success rate is the acquired chemoresistance of these cancers during their progression. The mechanisms responsible for this acquired chemoresistance are numerous, including efflux pumps, repair mechanisms, survival pathways (PI3K/AKT, MAPK, EGFR, mTOR, estrogen signaling) and tumor suppressors (P53 and Par-4). To overcome these resistances, a new type of therapy has emerged named targeted therapy. The principle of targeted therapy is simple, taking advantage of changes acquired in malignant cancer cells (receptors, proteins, mechanisms) by using compounds specifically targeting these, thus limiting their action on healthy cells. Targeted therapies are emerging and many clinical trials targeting these pathways, frequently involved in chemoresistance, have been tested on gynecological cancers. Despite some targets being less efficient than expected as mono-therapies, the combination of compounds seems to be the promising avenue. For instance, we demonstrate using ChIP-seq analysis that estrogen downregulate tumor suppressor Par-4 in hormone-dependent cells by directly binding to its DNA regulatory elements and inhibiting estrogen signaling could reinstate Par-4 apoptosis-inducing abilities. This review will focus on the chemoresistance mechanisms and the clinical trials of targeted therapies associated with these, specifically for endometrial and ovarian cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Mechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“BRCA1 and BRCA2 are a known genes involved in an error-free repair mechanism via homologous recombination for double strand DNA breaks [70].”
BackgroundHirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
Dauvois, S., White, R., & Parker, M. G. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.4.1377 · Cited by 522
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390 · cited 1×
“The response rate obtained was of 35% and half of the patients were free of progression after 6 months [214].”
BackgroundBedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications
Xiao, X., Melton, D. W., & Gourley, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.003 · Cited by 89
Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer
Leffers, N., Vermeij, R., Hoogeboom, B., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.25980 · Cited by 60 · cited 1×
“Following analyses indicated that the administration of P53-SLP did not enhance the efficiency of chemotherapy treatments, thus was not able to overcome the chemoresistance of advanced ovarian cancer patients [293].”
Background
Cited by
Akt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy
Zhao, Y., Li, Y., Zhang, R., Wang, F., Wang, T., & Jiao, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254995 · Cited by 458
pH-Responsive Polymer Nanomaterials for Tumor Therapy
Chu, S., Shi, X., Tian, Y., & Gao, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855019 · Cited by 300
pH-Responsive Natural Polymers as Versatile Carriers for Drug Delivery in Breast Cancer: A Review
Velapure, P. D., Chakote, S. R., Kansal, D., Barooah, A., Pawde, D. M., & Bobade, C. D. (2026) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00427-w · Cited by 5
Metadata
- Authors
- Brasseur, K., Gévry, N., & Asselin, E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-19
- Volume
- 8
- Issue
- 3
- Pages
- 4008-4042
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2563277046
- Cited by
- 224
- References
- 20
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.